Published in PLoS One on October 24, 2012
Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget (2014) 0.95
Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biol Med (2013) 0.89
miR-331-3p regulates expression of neuropilin-2 in glioblastoma. J Neurooncol (2013) 0.86
microRNA-7 suppresses the invasive potential of breast cancer cells and sensitizes cells to DNA damages by targeting histone methyltransferase SET8. J Biol Chem (2013) 0.85
microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget (2015) 0.84
Differential transcriptional effects of EGFR inhibitors. PLoS One (2014) 0.83
miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget (2016) 0.83
Clinical Potential of microRNA-7 in Cancer. J Clin Med (2015) 0.82
MicroRNA-7/NF-κB signaling regulatory feedback circuit regulates gastric carcinogenesis. J Cell Biol (2015) 0.82
microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB. Oncotarget (2016) 0.82
Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer? World J Clin Oncol (2015) 0.78
Suppression of MicroRNA-7 (miR-7) Biogenesis by Nuclear Factor 90-Nuclear Factor 45 Complex (NF90-NF45) Controls Cell Proliferation in Hepatocellular Carcinoma. J Biol Chem (2016) 0.78
Roles of mitochondrial transcription factor A and microRNA‑590‑3p in the development of colon cancer. Mol Med Rep (2016) 0.77
EGF receptor ligands: recent advances. F1000Res (2016) 0.77
MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression. J Clin Med (2015) 0.76
miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression. Oncotarget (2017) 0.75
Circular RNAs: Biogenesis, Function and Role in Human Diseases. Front Mol Biosci (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet (2011) 9.79
Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol (1989) 7.47
A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res (2003) 6.76
miRNAs in human cancer. J Pathol (2010) 6.02
Signal transduction through MAP kinase cascades. Adv Cancer Res (1998) 5.65
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med (2012) 5.46
Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res (2008) 5.46
Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res (1981) 5.08
AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A (2001) 4.88
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res (2008) 4.81
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther (2001) 4.37
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol (2006) 3.35
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A (2008) 3.08
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem (2008) 2.76
MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun (2007) 2.75
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A (2010) 2.72
Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol (2009) 2.57
MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56
MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res (2008) 2.32
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis (2008) 2.30
Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ (2005) 2.03
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J (2010) 1.91
A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer (1972) 1.86
Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck. Br J Cancer (1981) 1.70
Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol (2012) 1.69
miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res (2010) 1.54
MicroRNAs and endocrine biology. J Endocrinol (2005) 1.47
Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther (2011) 1.29
MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One (2012) 1.27
The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem (2011) 1.20
The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology (2004) 1.19
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res (2004) 1.13
Preparation of pure cell cultures by cloning. Methods Cell Sci (2000) 1.11
Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. Oncogene (2011) 1.09
microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol (2011) 1.07
Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. J Biol Chem (2011) 1.04
Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res (2000) 1.04
EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs (2008) 1.04
MicroRNA regulation of growth factor receptor signaling in human cancer cells. Methods Mol Biol (2011) 0.98
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett (2012) 0.95
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer. J Oncol (2012) 0.95
Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer (1991) 0.92
CK2 binds, phosphorylates, and regulates its pivotal substrate Cdc37, an Hsp90-cochaperone. Mol Cell Biochem (2005) 0.90
Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther (2007) 0.90
New promising molecular targets in head and neck squamous cell carcinoma. Curr Opin Oncol (2012) 0.90
The role of serum response factor in hepatocellular carcinoma: implications for disease progression. Int J Oncol (2010) 0.89
Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells. Int J Biochem Cell Biol (2011) 0.87
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat (2011) 0.86
Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Clin Transl Sci (2009) 0.82
Predicting microRNA targets in time-series microarray experiments via functional data analysis. BMC Bioinformatics (2009) 0.81
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature (2007) 3.08
Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem (2008) 2.76
Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med (2005) 2.65
Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Res Treat (2013) 2.05
MRNA stability and the control of gene expression: implications for human disease. Neurochem Res (2002) 1.94
Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3'-untranslated region of the androgen receptor messenger RNA. J Biol Chem (2002) 1.57
SLIRP, a small SRA binding protein, is a nuclear receptor corepressor. Mol Cell (2006) 1.57
Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol (2009) 1.36
The 3'-untranslated region of p21WAF1 mRNA is a composite cis-acting sequence bound by RNA-binding proteins from breast cancer cells, including HuR and poly(C)-binding protein. J Biol Chem (2002) 1.23
Thyrotropin and thyroid antibodies as predictors of hypothyroidism: a 13-year, longitudinal study of a community-based cohort using current immunoassay techniques. J Clin Endocrinol Metab (2010) 1.21
The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem (2011) 1.20
miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem (2009) 1.19
Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Mol Cell (2012) 1.19
Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab (2012) 1.16
Nontransferrin-bound iron uptake by hepatocytes is increased in the Hfe knockout mouse model of hereditary hemochromatosis. Blood (2004) 1.15
Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther (2013) 1.14
Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation. BMC Struct Biol (2007) 1.09
Sequence requirements for RNA binding by HuR and AUF1. J Biochem (2012) 1.09
miRNA-7-5p inhibits melanoma cell migration and invasion. Biochem Biophys Res Commun (2012) 1.07
Thyroid dysfunction and serum lipids: a community-based study. Clin Endocrinol (Oxf) (2005) 1.07
Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab (2007) 1.07
The ROQUIN family of proteins localizes to stress granules via the ROQ domain and binds target mRNAs. FEBS J (2010) 1.06
Steroid Receptor RNA Activator - A nuclear receptor coregulator with multiple partners: Insights and challenges. Biochimie (2011) 1.05
Significant inverse relationship between serum free T4 concentration and body mass index in euthyroid subjects: differences between smokers and nonsmokers. Clin Endocrinol (Oxf) (2008) 1.05
Ectopic parathyroid adenoma localised with sestamibi SPECT and image-fused computed tomography. Med J Aust (2003) 1.02
Toward the discrimination of early melanoma from common and dysplastic nevus using fiber optic diffuse reflectance spectroscopy. J Biomed Opt (2006) 1.01
Subclinical thyroid dysfunction and blood pressure: a community-based study. Clin Endocrinol (Oxf) (2006) 1.00
Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer. Nucleic Acids Res (2010) 0.99
Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. Biochem Soc Trans (2008) 0.99
Investigations of thyroid hormones and antibodies based on a community health survey: the Busselton thyroid study. Clin Endocrinol (Oxf) (2006) 0.98
RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators. Proc Natl Acad Sci U S A (2013) 0.98
SRA and its binding partners: an expanding role for RNA-binding coregulators in nuclear receptor-mediated gene regulation. Crit Rev Biochem Mol Biol (2009) 0.98
MicroRNA regulation of growth factor receptor signaling in human cancer cells. Methods Mol Biol (2011) 0.98
A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria. Biochem Pharmacol (2007) 0.97
Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol Endocrinol (2013) 0.97
The androgen receptor mRNA. Bioessays (2004) 0.96
Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res (2008) 0.96
Identification of suitable endogenous control genes for microRNA expression profiling of childhood medulloblastoma and human neural stem cells. BMC Res Notes (2012) 0.94
Parity and the risk of autoimmune thyroid disease: a community-based study. J Clin Endocrinol Metab (2005) 0.93
Integrated analysis of miRNA and mRNA expression in childhood medulloblastoma compared with neural stem cells. PLoS One (2011) 0.93
Erythroid defects in TRalpha-/- mice. Blood (2008) 0.92
The acute box cis-element in human heavy ferritin mRNA 5'-untranslated region is a unique translation enhancer that binds poly(C)-binding proteins. J Biol Chem (2005) 0.92
Downstream targets of heterogeneous nuclear ribonucleoprotein A2 mediate cell proliferation. Mol Carcinog (2009) 0.92
The RNA coregulator SRA, its binding proteins and nuclear receptor signaling activity. IUBMB Life (2008) 0.90
A meta-analysis of the associations between common variation in the PDE8B gene and thyroid hormone parameters, including assessment of longitudinal stability of associations over time and effect of thyroid hormone replacement. Eur J Endocrinol (2011) 0.89
HADHB, HuR, and CP1 bind to the distal 3'-untranslated region of human renin mRNA and differentially modulate renin expression. J Biol Chem (2003) 0.89
Contribution of the first K-homology domain of poly(C)-binding protein 1 to its affinity and specificity for C-rich oligonucleotides. Nucleic Acids Res (2012) 0.88
miR-331-3p regulates expression of neuropilin-2 in glioblastoma. J Neurooncol (2013) 0.86
The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma. Tumour Biol (2013) 0.86
Neurophysiological evidence for cognitive and brain functional adaptation in adolescents living at high altitude. Clin Neurophysiol (2011) 0.85
Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells. J Biol Chem (2012) 0.85
Regulation of ErbB receptor signalling in cancer cells by microRNA. Curr Opin Pharmacol (2010) 0.83
ADAM28 is elevated in humans with the metabolic syndrome and is a novel sheddase of human tumour necrosis factor-α. Immunol Cell Biol (2012) 0.82
Significant association between thyroid hormones and erythrocyte indices in euthyroid subjects. Clin Endocrinol (Oxf) (2012) 0.82
Matrigel basement membrane matrix influences expression of microRNAs in cancer cell lines. Biochem Biophys Res Commun (2012) 0.82
Loss of the nuclear receptor corepressor SLIRP compromises male fertility. PLoS One (2013) 0.81
Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocr Relat Cancer (2012) 0.81
Limited iron export by hepatocytes contributes to hepatic iron-loading in the Hfe knockout mouse. J Hepatol (2005) 0.79
PRMT2 and RORγ expression are associated with breast cancer survival outcomes. Mol Endocrinol (2014) 0.79
Overexpression and knock-down studies highlight that a disintegrin and metalloproteinase 28 controls proliferation and migration in human prostate cancer. Medicine (Baltimore) (2016) 0.78
RNA-binding proteins that target the androgen receptor mRNA. IUBMB Life (2002) 0.77
Homocysteine and vitamin status in older people in Perth. Med J Aust (2004) 0.75